GSK’s (GSK) “Hold” Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reiterated their hold rating on shares of GSK (LON:GSK) in a report published on Monday morning, Marketbeat Ratings reports. They currently have a GBX 1,950 price target on the stock.

Other equities analysts have also issued reports about the company. Citigroup cut their price target on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a research note on Thursday, May 28th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, GSK has an average rating of “Hold” and an average price target of GBX 2,041.43.

GSK Stock Down 1.1%

GSK opened at GBX 2,007 on Monday. The company has a 50 day moving average of GBX 1,937.92 and a 200 day moving average of GBX 1,991.49. The company has a market cap of £80.39 billion, a PE ratio of 14.12, a price-to-earnings-growth ratio of 1.24 and a beta of 0.30. GSK has a 12 month low of GBX 1,288.61 and a 12 month high of GBX 2,282. The company has a current ratio of 0.79, a quick ratio of 0.73 and a debt-to-equity ratio of 106.74.

GSK (LON:GSK) last released its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. On average, sell-side analysts expect that GSK will post 175.980975 EPS for the current year.

Insider Activity at GSK

In other news, insider Jeannie Lee acquired 802 shares of GSK stock in a transaction that occurred on Monday, June 22nd. The stock was bought at an average price of GBX 5,069 per share, with a total value of £40,653.38. Also, insider Jonathan Symonds bought 1,550 shares of the firm’s stock in a transaction that occurred on Friday, June 19th. The shares were purchased at an average cost of GBX 1,935 per share, for a total transaction of £29,992.50. Over the last 90 days, insiders bought 3,625 shares of company stock valued at $13,495,004. Corporate insiders own 0.20% of the company’s stock.

More GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Broker support: Jefferies reaffirmed its “buy” rating and set a GBX 2,500 price target, indicating substantial potential upside from recent trading levels. Digital Look broker views
• Positive Sentiment: Pipeline progress: Partner Hansoh reported positive late-stage trial results for a bone-cancer therapy licensed by GSK. The outcome supports the company’s effort to replenish its drug pipeline and could strengthen future growth prospects. GSK licensed cancer therapy trial report
• Positive Sentiment: Efficiency and margin focus: GSK plans approximately £1.9 billion in annual savings, or about $2.5 billion in restructuring-related savings, primarily from mature products, procurement and its supply chain. Management also raised its margin outlook, with savings intended to fund research and development and accelerate new medicines. GSK savings and R&D report
• Neutral Sentiment: Quarterly results: GSK reported quarterly earnings of GBX 54.10 per share, alongside a 17.78% net margin and 35.78% return on equity. The available report does not provide a comparable earnings estimate or detailed outlook change. GSK quarterly earnings report
• Neutral Sentiment: Analyst disagreement: Deutsche Bank maintained a “hold” rating, contrasting with Jefferies’ bullish view and highlighting uncertainty around GSK’s restructuring and longer-term growth. Deutsche Bank GSK rating report
• Negative Sentiment: Execution and workforce risks: GSK plans to close its historic Stevenage site, move research activity to Cambridge and cut jobs. While these moves may reduce costs, they could disrupt operations, trigger restructuring expenses and create execution risks. GSK Stevenage site closure report
• Negative Sentiment: Patent-cliff concerns: The cost-cutting program is partly intended to prepare GSK for upcoming loss-of-exclusivity pressures. Investors may remain cautious until the company demonstrates that savings can offset product erosion and produce successful replacement drugs. GSK restructuring and patent cliff report

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.